-19.9%
NOW vs MRNA
+221.0%
-240.9%
-64.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | -3.4% | +5.0% | +1.7% |
| 7D | +0.3% | -12.1% | +12.4% | +0.8% |
| 30D | -27.0% | -1.3% | -25.7% | -27.1% |
| 3M | -19.6% | +250.9% | -270.6% | -27.3% |
| 6M | +17.5% | +343.0% | -325.6% | +4.2% |
| YTD | -33.3% | +657.4% | -690.7% | -44.0% |
| 1Y | -39.8% | +794.9% | -834.7% | -50.5% |
| 3Y | -19.9% | +218.1% | -238.1% | -29.0% |
| All | -19.9% | +221.0% | -240.9% | -29.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling